SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced that the Company exhibited the MicroThermX® Microwave Ablation System at the World Conference on Interventional Oncology (WCIO) meeting, which was held June 9 to June 12, 2010, in Philadelphia, Pennsylvania.
BSD has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA) for premarket clearance of the Company's MicroThermX® Microwave Ablation System (MTX) for ablation of soft tissue. The 510(k) clearance is pending. Clearance from the FDA of BSD Medical’s 510(k) Premarket Notification submission will authorize the commercial sale of the MTX in the United States.
The MTX was designed to provide an optimized system that is targeted to the growing therapeutic interventional oncology market. The interventional oncology worldwide market for 2009 was estimated at $210 million, and this market is projected to grow to $480 million by 2015.
About the World Conference on Interventional Oncology (WCIO)
The WCIO is an international meeting that was organized to provide a scientific forum where international experts from all oncologic disciplines can gather and advance the future of cancer therapy by exploring the synergy of minimally invasive treatments with both traditional and other new oncologic therapies.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (remove or vaporize) soft tissue. The Company has extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
CONTACT:
BSD Medical Corporation
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
[email protected]
KEYWORDS: United States North America Utah
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Oncology FDA General Health
MEDIA:
| Logo |